Disclosures. All authors: No reported disclosures.

739. Middle East Respiratory Syndrome Coronavirus Infection Profile in Qatar: A 7-Year Retrospective Study

N. E. Elrhaz, MD, M. Al Saadi, MD, H. B. Al-subaie, MD, S. K. S. Al Jaber, MD, Infectious Disease, Hamad Medical Corporation, Doha, Qatar, Infectious Disease, University Hospitals, Case Western Reserve University, Cleveland, Ohio, Internal Medicine-Infectious Disease, Weill Cornell Medical College-QATAR and Communicable Disease Center-Hamad Medical Corporation, Doha, Qatar

Session: 69. Respiratory Infections: Viral
Thursday, October 4, 2018: 12:30 PM

Background. A deadly zoonotic Middle East respiratory syndrome coronavirus (MERS-CoV) had emerged over the last 7 years in the Arabian Peninsula. As of February 28, 2018, 2,182 cases of MERS-CoV infection (with 779 deaths) in 27 countries were reported to WHO worldwide. The objectives of this study were to identify the clinical and epidemiological characteristics of MERS-CoV infection as well as determine its clinical outcome.

Methods. This was a retrospective-observational study of all laboratory confirmed cases of MERS-CoV infection conducted at the main seven hospitals in the State of Qatar from January, 2012 to April 2018. We used the Fast Track diagnostics real-time reverse-transcription polymerase chain reaction (rRT-PCR), targeting the upE infection was documented in a 15(57.6%) children aged <1 year age and 11(42.4%) children at ≥2 years age. Twenty-five percent patients were on hemodialysis and 16% needed extra-corporeal membrane oxygenation. Thirty-eight had travel history and probable risk factors were collected and analyzed by standard statistical methods.

Results. The mean annual incidence was 1.7 per 100,000 person-years. Among the 24 confirmed cases of MERS-CoV, males constituted the vast majority of cases (23 males) with a median age of 52 years (range 22–74). Fifty percent of the cases were Qatari and 42% reside in the same region. 67% of the cases had contact with camels, and 21% had no contact with MERS-CoV-infected patient. Thirty-eight had travel history within 2 weeks of symptoms onset to the Kingdom of Saudi Arabia. Fifty percent were smokers and 42% had comorbidities.

The median symptoms duration was 4.5 days. Most of the patient presented with the following symptoms, were fever was the most common presentation, followed by cough, SOB, diarrhea, abdominal pain and headache, 96%, 83%, 33%, 8%, 8% and 4% respectively. All patients were admitted to a tertiary hospital with a median hospital stay 4 days (8–97). Forty-five percent patients developed severe sepsis with multi-organ failure and needed ICU admission. Fifty percent patients developed acute kidney injury, 29% patients were on hemodialysis and 16% needed extra-corporeal membrane oxygenation. Thirty-three percent patients died. The rest of patients had recovered from the infection and discharged home. Among those who died all had one or more comorbidities.

Conclusion. MERS-CoV infection is a rare infection in the State of Qatar, seen in both Qatari and expatriates with and without travel history. The infection in patients with comorbidities carries high mortality.

Disclosures. All authors: No reported disclosures.

740. Impact of the 2014 American Academy of Pediatrics Guidance on Respiratory Syncytial Virus Hospitalization Rates for Preterm Infants <29 Weeks Gestational Age at Birth: 2012–2016

Mitchell Goldstein, MD6; Leonard R. Kivlov, MD5; Jaime Fergie, MD2; Lance Brannam, PhD7; Christopher S. Ambrose, MD, MBA4; Sally Wade, MPH4 and Amanda Kong, MPH7; Loma Linda University Children’s Hospital, Loma Linda, California, Children’s Medical Center, NYU Winthrop, Mineola, New York, Driscoll Children’s Hospital, Corpus Christi, Texas, AstraZeneca, Gaithersburg, MD, Department of US Medical Affairs, AstraZeneca, Gaithersburg, MD, Wade Outcomes Research and Consulting, Salt Lake City, Utah, Truven Health Analytics, an IBM Company, Cambridge, Massachusetts

Session: 69. Respiratory Infections: Viral
Thursday, October 4, 2018: 12:30 PM

Background. Respiratory syncytial virus (RSV) infection is a major cause of serious lower respiratory disease in infancy and early childhood and Mycoplasma pneumoniae (M. pneumoniae) is a common cause of respiratory tract infections in all age groups. The study was conducted to determine the role of RSV and M. pneumoniae in pediatric lower respiratory tract infections employing serological tests, polymerase chain reaction (PCR) and reverse transcriptase PCR analysis.

Methods. In this prospective study, 75 children aged 1 month to 5 years with acute lower respiratory tract infections (LRTIs) were investigated. Paired serum samples were obtained on admission and after 4–6 weeks to assay for M. pneumoniae antibodies. Nasopharyngeal aspirates were obtained for the detection of RSV antigen by using the immunochromatographic test, reverse transcriptase-polymerase chain reaction (RT-PCR) for RSV and M. pneumoniae by PCR.

Results. RSV infection was positive in 20(60.6%) children aged <1 year and 13(39.4%) aged 2–5 years, the sensitivity of RSV antigen by immunochromatography test was 0.360. M. pneumoniae infection was documented in a 15(57.6%) children aged <1 year age and 11(42.4%) in age 2–5 years which was statistically significant (P = 0.026). Clinical and radiological features among RSV and M. pneumoniae positive and negative cases were comparable. Thirty-four (19%) children were positive for RSV antigen and by RT-PCR and 3(12%) only by RT-PCR. Serological evidence of M. pneumoniae infection was documented in 24(32%) children. M. pneumoniae PCR was positive in 8 (10.6%) patients. Together, serology and PCR detected M. pneumoniae in 26(34.6%) children. Considering RT-PCR as a diagnostic standard, the sensitivity of RSV antigen by immunochromatography was 90.06%, specificity 100%, positive predictive value 100% and a negative predictive value of 93.3%. The sensitivity of M. pneumoniae serology was 75%, specificity 73.3%, positive predictive value 25% and a negative predictive value of 96% considering PCR as a diagnostic standard.

Conclusion. Our data underline the role of RSV and M. pneumoniae as the major cause of community-acquired lower respiratory tract infections in children aged <5 years.

Disclosures. All authors: No reported disclosures.

738. Role of Respiratory Syncytial Virus and Mycoplasma pneumoniae in Pediatric Community-Acquired Lower Respiratory Tract Infections

Sanchit Kumar, MBBS, MD(Students)1, Anita Chakravarti, MD,2 Surinder Kumar, MD, DM, MRCP1 and Seema Kapoor, MD,1 Medicine, All India Institute of Medical Sciences, New Delhi, India,1 Microbiology, Maulana Azad Medical College, New Delhi, India, Pediatrics, Department of Pediatrics, Maulana Azad Medical College, New Delhi, India

Session: 69. Respiratory Infections: Viral
Thursday, October 4, 2018: 12:30 PM

Background. Respiratory syncytial virus (RSV) infection is a major cause of serious lower respiratory disease in infancy and early childhood and Mycoplasma pneumoniae (M. pneumoniae) is a common cause of respiratory tract infections in all age groups. This study was conducted to determine the role of RSV and M. pneumoniae in pediatric lower respiratory tract infections employing serological tests, polymerase chain reaction (PCR) and reverse transcriptase PCR analysis.

Methods. In this prospective study, 75 children aged 1 month to 5 years with acute lower respiratory tract infections (LRTIs) were investigated. Paired serum
Background. In 2014, the American Academy of Pediatrics stopped recommending RSV immunoprophylaxis (RSV IP) for otherwise healthy infants 29–34 weeks gestational age (wGA), while continuing to recommend RSV IP for infants born at <29 wGA. The decline in RSV IP and associated increase in RSV hospitalizations (RSVH) among infants 29–34 wGA have been described previously, but potential effects of the 2014 guidance change on preterm infants <29 wGA are unknown. This study compared 2012–2014 and 2014–2016 outpatient RSV IP use as well as RSVH rates relative to term infants among otherwise healthy <29 wGA infants.

Methods. Infants born from July 1, 2011 to June 30, 2016 were followed from birth hospitalization discharge through their first year of life in the MarketScan Commercial (COM) and Multistate Medicaid (MED) databases. DRG and ICD codes identified term and <29 wGA infants at birth. RSV IP receipt was derived from pharmacy and outpatient medical claims (inpatient RSV IP data were unavailable). RSVH were derived from inpatient medical claims. RSVH rates were calculated for three chronologic age (CA) groups: <3 months, 3–<6 months, and 6–<12 months. RSVH rate ratios for 2012–2014 and 2014–2016 were calculated for <29 wGA infants using healthy term infants 0–<12 months of age as a reference category.

Results. Outpatient RSV IP receipt fell after 2014 for <29 wGA infants across all CA categories, with the greatest decline observed among infants <3 months CA (Table 1). Greater RSVH rates for <29 wGA infants relative to term infants were observed after 2014 (Figures 1 and 2), even though RSV IP continued to be recommended. The effects were greatest for infants <3 months CA and those insured by Medicaid.

Funded by AstraZeneca

Table 1. Percentage of <29 wGA Infants Receiving Outpatient RSV IP in 2012–2014 vs. 2014–2016

|                  | COM 2012–2014 | COM 2014–2016 | P-value* |
|------------------|---------------|---------------|----------|
| <3 months, %     | 19.8          | 14.6          | 0.05     |
| 3 to <6 months, %| 46.4          | 43.0          | 0.24     |
| 6 to <12 months, %| 478           | 42.3          | 0.12     |

Conclusion. Outpatient RSV IP decreased and RSVH relative to term infants increased among otherwise healthy <29 wGA infants following the 2014 policy change, even though RSV IP continued to be recommended. The effects were greatest for infants <3 months CA and those insured by Medicaid.

Disclosures. M. Goldstein, AstraZeneca/MedImmune: Consultant, Research grant and Support Research. L. R. Kriol, AstraZeneca/MedImmune: Consultant, Research grant and Research support. J. Fergie, AstraZeneca/MedImmune: Consultant and Speaker’s Bureau, Research grant and Research support. L. Bramann, AstraZeneca: Employee, Salary and Stocks. C. S. Ambrose, AstraZeneca: Employee, Salary and Stocks. S. Wade, Wade Outcomes Research and Consulting contracted by Truven: Consultant, Consulting fee. A. Kong, Truven Health Analytics, an IBM Company: Employee, Salary.

741. Impact of Adenovirus Co-detections on Illness Severity
Varvara Probst, MD1; Bhinnata Pyia, MPH1; Laura Stewart, PhD2; Susan Gerber, MD2; Brian Rha, MD, MSPH1; Joana Yu, MPH1; Suman Das, PhD2; Angela P. Campbell, MD, MPH, FIDSA3; John V. Williams, MD4 and Natasha B. Halasa, MD, MPH, FIDSA5. **Pediatic Infectious Disease, Vanderbilt University Medical Center, Nashville, Tennessee, Vanderbilt University Medical Center, Nashville, Tennessee, 1Centers for Disease Control and Prevention, Atlanta Georgia, Georgia, 2Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, 3Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, 4Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, 5Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 6Vanderbilt University School of Medicine, Nashville, Tennessee.

Session: 69. Respiratory Infections: Viral
Thursday, October 4, 2018: 12:30 PM

Background. Human adenovirus (AdV) is a common pathogen among children with acute respiratory illnesses (ARI) and is often associated with co-detection with other respiratory viral pathogens. We sought to compare demographic and clinical characteristics in children with ARI who had single-AdV vs. AdV-co-detection with other viruses.

Methods. Children <18 years with fever and/or ARI were enrolled in Vanderbilt Children’s Hospital inpatient setting from 2015 to 2018 and emergency department from 2016 to 2018. Interviews were conducted using standardized case report forms. Nose and throat swab specimens were collected and tested by RT-qPCR for common respiratory pathogens (AdV, RSV, HRV, hMPV, PIV1–4 and Influenza).

Results. Of 2,740 ARI cases, 174 were positive for AdV [88 (51%) single detection], with 53% male, 47% White, 36% Black, 30% Hispanic and median age of 17.2 months. Co-detected pathogens in AdV-positive specimens were RSV (15%), HRV (1%), influenza (3%), PIV1 (1%), PIV2 (0.6%), PIV3 (1.7%), and PIV4 (0.4%), hMPV (0.5%). Subjects with single-AdV detection were less likely to have a underlying medical condition (42% vs. 24%, P < 0.05). Table 1 compares clinical presentation and severity of single-AdV and AdV-co-detection cases.

|                  | AdV-Single | AdV-co-Detection | P-value* |
|------------------|------------|------------------|----------|
| n (%)            | 88 (%)     | 86 (%)           |          |

Fever
Cough
Dyspnea
Wheezing
Chest in-drawing
Nasal congestion/ runny nose
Diarrhea
Supplemental oxygen
Admitted (2015–2016)
ICU Admission (2015–2016)
Admitted (2016–2018)
ICU admission (2016–2018)

Conclusion. Patients with single-AdV detection were less likely to present with ARI symptoms and require oxygen, but were more likely to have underlying medical conditions compared with AdV-co-detection. Further studies to type AdV isolates will help elucidate the role of specific adenovirus types associated with co-detections and inform epidemiological information for future vaccine initiatives.

Disclosures. J. V. Williams, Quidel: Board Member, Consulting fee. GlaxoSmithKline: Consultant, Consulting fee. N. B. Halasa, sanofi pasteur: Investigator, Research support. GSK: Consultant, Consulting fee. Moderna: Consultant, Consulting fee.

742. “Troponin Leaks” in Patients with Acute Respiratory Viral Infections Enrolled in SUPERNOVA: A Marker of Worse Clinical Outcomes
Ernesto Ruiz, MD1, Bashar Lengei, MD1, Tiffany Gray, RN1, Malwisch Mustaq, MD2, Daniel Mushker, MD, FIDSA3 and MariaRodriguez-Barradas, MD, FIDSA4. 1MEDVAMC, Houston, Texas, 2Infectious Disease Section, Baylor College of Medicine, Houston, Texas, 3Baylor College of Medicine, Houston, Texas, 4Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas.

Session: 69. Respiratory Infections: Viral
Thursday, October 4, 2018: 12:30 PM

Background. Cardiac troponin I (cTnI) is a specific marker of cardiac muscular injury. Many patients hospitalized with acute respiratory illness (ARI) have elevated cTnI levels but do not meet EKG criteria for an acute ischemic cardiac event. Troponin leaks could be due to demand ischemia or acute inflammation of the myocardium. We hypothesized that patients with viral ARI and elevated cTnI have worse cardiopulmonary outcomes than those with viral ARI and normal cTnI.

Methods. From November 11, 2016—September 30, 2017 nasopharyngeal swabs from patients enrolled in SUPERNOVA ARI Study, a CDC/2-VA site, active surveillance platform to evaluate the incidence of viral infection in patients hospitalized with symptoms and/or signs of ARI, were tested using a FilmArray Respiratory Panel. Based on detection of any virus, patients were categorized as positive (vPCR+) or negative (vPCR–). Patient enrolled at the Houston site with cTnI obtained <48 hours of

**AdV-Single**
**AdV-co-Detection**
**P-value**

Fever
Cough
Dyspnea
Wheezing
Chest in-drawing
Nasal congestion/runny nose
Diarrhea
Supplemental oxygen
Admitted (2015–2016)
ICU Admission (2015–2016)
Admitted (2016–2018)
ICU admission (2016–2018)

Conclusion. Patients with single-AdV detection were less likely to present with ARI symptoms and require oxygen, but were more likely to have underlying medical conditions compared with AdV-co-detection. Further studies to type AdV isolates will help elucidate the role of specific adenovirus types associated with co-detections and inform epidemiological information for future vaccine initiatives.